KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Cash: 2011-2024

Historic Change in Cash for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $62.5 million.

  • Esperion Therapeutics' Change in Cash rose 114.32% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 274.91%. This contributed to the annual value of $62.5 million for FY2024, which is 247.00% up from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Change in Cash is $62.5 million, which was up 247.00% from -$42.5 million recorded in FY2023.
  • Esperion Therapeutics' Change in Cash's 5-year high stood at $137.9 million during FY2020, with a 5-year trough of -$134.1 million in FY2022.
  • For the 3-year period, Esperion Therapeutics' Change in Cash averaged around -$38.0 million, with its median value being -$42.5 million (2023).
  • Per our database at Business Quant, Esperion Therapeutics' Change in Cash slumped by 191.12% in 2022 and then surged by 247.00% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Change in Cash (Yearly) stood at $137.9 million in 2020, then plummeted by 133.41% to -$46.1 million in 2021, then slumped by 191.12% to -$134.1 million in 2022, then surged by 68.29% to -$42.5 million in 2023, then skyrocketed by 247.00% to $62.5 million in 2024.